A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression

References

• Gottlieb A, Stein GY, Ruppin E, et al. PREDICT: A method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol. 2011;7:496.
   PubMed Web of Science ®Google Scholar
• Connor DF. Aggression and antisocial behavior in children and adolescents: research and treatment. New York, NY: The Guilford Press; 2002.
   Google Scholar
• Bambauer KZ, Connor DF. Characteristics of aggression in clinically referred children. CNS Spectr. 2005 Sep;10(9):709–718.
   PubMed Web of Science ®Google Scholar
• Jensen PS, Youngstrom EA, Steiner H, et al. Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. J Am Acad Child Adolesc Psychiatry. 2007 Mar;46(3):309–322.
   PubMed Web of Science ®Google Scholar
• Saylor KE, Amann BH. Impulsive aggression as a comorbidity of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2016 Feb;26(1):19–25.
   PubMed Web of Science ®Google Scholar
• Felthous AR, Stanford MS. A proposed algorithm for the pharmacotherapy of impulsive aggression. J Am Acad Psychiatry Law. 2015 Dec;43(4):456–467.
   PubMed Web of Science ®Google Scholar
• Knapp P, Chait A, Pappadopulos E, et al. Treatment of maladaptive aggression in youth: CERT guidelines i. Engagement, assessment, and management. Pediatrics. 2012 Jun;129(6):e1562–76.
   PubMed Web of Science ®Google Scholar
• Malone RP, Bennett DS, Luebbert JF, et al. Aggression classification and treatment response. Psychopharmacol Bull. 1998;34(1):41–45.
   PubMedGoogle Scholar
• Vitiello B, Behar D, Hunt J, et al. Subtyping aggression in children and adolescents. J Neuropsychiatry Clin Neurosci. 1990 Spring;2(2):189–192.
   PubMedGoogle Scholar
• Raine A, Dodge K, Loeber R, et al. The reactive-proactive aggression questionnaire: differential correlates of reactive and proactive aggression in adolescent boys. Aggress Behav. 2006 Apr 01;32(2):159–171.
   PubMed Web of Science ®Google Scholar
• Bushman BJ, Anderson CA. Is it time to pull the plug on the hostile versus instrumental aggression dichotomy? Psychol Rev. 2001 Jan;108(1):273–279.
   PubMed Web of Science ®Google Scholar
• Marsee MA, Barry CT, Childs KK, et al. Assessing the forms and functions of aggression using self-report: factor structure and invariance of the Peer Conflict Scale in youths. Psychol Assess. 2011 Sep;23(3):792–804.
   PubMed Web of Science ®Google Scholar
• Barratt ES, Stanford MS, Dowdy L, et al. Impulsive and premeditated aggression: A factor analysis of self-reported acts. Psychiatry Res. 1999 May 31;86(2):163–173.
   PubMed Web of Science ®Google Scholar
• Connor DF. On the challenge of maladaptive and impulsive aggression in the clinical treatment setting. J Child Adolesc Psychopharmacol. 2016 Feb;26(1):2–3.
   PubMed Web of Science ®Google Scholar
• Blair RJ. The neurobiology of impulsive aggression. J Child Adolesc Psychopharmacol. 2016 Feb;26(1):4–9.
   PubMed Web of Science ®Google Scholar
• Bidzan L, Bidzan M, Pachalska M. Aggressive and impulsive behavior in Alzheimer’s disease and progression of dementia. Med Sci Monit. 2012 Mar;18(3):CR182–9.
   PubMed Web of Science ®Google Scholar
• James LM, Strom TQ, Leskela J. Risk-taking behaviors and impulsivity among veterans with and without PTSD and mild TBI. Mil Med. 2014 Apr;179(4):357–363.
   PubMed Web of Science ®Google Scholar
• Insel TR. The NIMH research domain criteria (RDoC) project: precision medicine for psychiatry. Am J Psychiatry. 2014 Apr;171(4):395–397.
   PubMed Web of Science ®Google Scholar
• Cuthbert BN, Kozak MJ. Constructing constructs for psychopathology: the NIMH research domain criteria. J Abnorm Psychol. 2013 Aug;122(3):928–937.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
   Google Scholar
• Krieger FV, Leibenluft E, Stringaris A, et al. Irritability in children and adolescents: past concepts, current debates, and future opportunities. Rev Bras Psiquiatr. 2013;35(Suppl 1):S32–9.
   PubMed Web of Science ®Google Scholar
• Axelson D, Findling RL, Fristad MA, et al. Examining the proposed disruptive mood dysregulation disorder diagnosis in children in the Longitudinal Assessment of Manic Symptoms study. J Clin Psychiatry. 2012 Oct;73(10):1342–1350.
   PubMed Web of Science ®Google Scholar
• Lahey BB, Pelham WE, Stein MA, et al. Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children. J Am Acad Child Adolesc Psychiatry. 1998 Jul;37(7):695–702.
   PubMed Web of Science ®Google Scholar
• Applegate B, Lahey BB, Hart EL, et al. Validity of the age-of-onset criterion for ADHD: A report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry. 1997 Sep;36(9):1211–1221.
   PubMed Web of Science ®Google Scholar
• Johnson VA, Kemp AH, Heard R, et al. Childhood- versus adolescent-onset antisocial youth with conduct disorder: psychiatric illness, neuropsychological and psychosocial function. PLoS One. 2015;10(4):e0121627.
   PubMed Web of Science ®Google Scholar
• Vidal-Ribas P, Brotman MA, Valdivieso I, et al. The status of irritability in psychiatry: A conceptual and quantitative review. J Am Acad Child Adolesc Psychiatry. 2016 Jul;55(7):556–570.
   PubMed Web of Science ®Google Scholar
• Jensen PS, Buitelaar J, Pandina GJ, et al. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: A systematic review of published clinical trials. Eur Child Adolesc Psychiatry. 2007 Mar;16(2):104–120.
   PubMed Web of Science ®Google Scholar
• Aman MG, Bukstein OG, Gadow KD, et al. What does risperidone ADD to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014 Jan;53(1):47–60 e1.
   PubMed Web of Science ®Google Scholar
• Pappadopulos E, Macintyre JC, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry. 2003 Feb;42(2):145–161.
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2018. Oslo, Norway: Norwegian Institute of Public Health 2018 [cited 2017 Dec 20].
   Google Scholar
• Schur SB, Sikich L, Findling RL, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: A review. J Am Acad Child Adolesc Psychiatry. 2003 Feb;42(2):132–144.
   PubMed Web of Science ®Google Scholar
• Supernus Pharmaceuticals, Inc. Supernus receives FDA fast track designation for SPN-810 [news release]. Rockville, MD: Globe Newswire; 2014.
   Google Scholar
• Comai S, Tau M, Pavlovic Z, et al. The psychopharmacology of aggressive behavior: A translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol. 2012 Apr;32(2):237–260.
   PubMed Web of Science ®Google Scholar
• Tardy M, Huhn M, Kissling W, et al. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2014 Jul;9(7):CD009268.
   Google Scholar
• Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry. 1984 Jul;41(7):650–656.
   PubMed Web of Science ®Google Scholar
• Khushu A, Powney MJ. Haloperidol for long-term aggression in psychosis. Cochrane Database Syst Rev. 2016 Nov;27(11):CD009830.
   Google Scholar
• Greenhill LL, Solomon M, Pleak R, et al. Molindone hydrochloride treatment of hospitalized children with conduct disorder. J Clin Psychiatry. 1985 Aug;46(8 Pt 2):20–25.
   PubMed Web of Science ®Google Scholar
• Stocks JD, Taneja BK, Baroldi P, et al. A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. J Child Adolesc Psychopharmacol. 2012 Apr;22(2):102–111.
   PubMed Web of Science ®Google Scholar
• Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. J Clin Psychiatry. 1985 Aug;46(8 Pt 2):4–7.
   PubMed Web of Science ®Google Scholar
• Scotto Rosato N, Correll CU, Pappadopulos E, et al. Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics. 2012 Jun;129(6):e1577–86.
   PubMed Web of Science ®Google Scholar
• Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007 May;46(5):558–565.
   PubMed Web of Science ®Google Scholar
• Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004 Summer;14(2):243–254.
   PubMed Web of Science ®Google Scholar
• Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009 Dec;124(6):1533–1540.
   PubMed Web of Science ®Google Scholar
• Kronenberger WG, Giauque AL, Lafata DE, et al. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: A prospective, open-label study. J Child Adolesc Psychopharmacol. 2007 Jun;17(3):334–347.
   PubMed Web of Science ®Google Scholar
• Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006 Jun;63(6):622–629.
   PubMed Web of Science ®Google Scholar
• Findling RL, Townsend L, Brown NV, et al. The Treatment of Severe Childhood Aggression study: 12 weeks of extended, blinded treatment in clinical responders. J Child Adolesc Psychopharmacol. 2017 Feb;27(1):52–65.
   PubMed Web of Science ®Google Scholar
• Gadow KD, Brown NV, Arnold LE, et al. Severely aggressive children receiving stimulant medication versus stimulant and risperidone: 12-month follow-up of the TOSCA trial. J Am Acad Child Adolesc Psychiatry. 2016 Jun;55(6):469–478.
   PubMed Web of Science ®Google Scholar
• van Schalkwyk GI, Beyer C, Johnson J, et al. Antipsychotics for aggression in adults: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb;81:452–458.
   Web of Science ®Google Scholar
• Findling RL, McBurnett K, White C, et al. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014 Jun;24(5):245–252.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Hirsch L, Gardner D, et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers. Can J Psychiatry. 2015 Feb;60(2):52–61.
   PubMed Web of Science ®Google Scholar
• Lam RP, Yip WL, Wan CK, et al. Dexmedetomidine use in the ED for control of methamphetamine-induced agitation. Am J Emerg Med. 2017 Apr;35(4):665 e1–665 e4.
   PubMed Web of Science ®Google Scholar
• Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila). 2000 Jan;39(1):15–25.
   PubMed Web of Science ®Google Scholar
• Ming X, Gordon E, Kang N, et al. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008 Aug;30(7):454–460.
   PubMed Web of Science ®Google Scholar
• Hammond FM, Bickett AK, Norton JH, et al. Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression. J Head Trauma Rehabil. 2014 Sep-Oct;29(5):391–399.
   PubMed Web of Science ®Google Scholar
• Hammond FM, Malec JF, Zafonte RD, et al. Potential impact of amantadine on aggression in chronic traumatic brain injury. J Head Trauma Rehabil. 2017 Sep/Oct;32(5):308–318.
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: A pooled analysis of 3 studies. J Clin Psychiatry. 2008 Mar;69(3):341–348.
   PubMed Web of Science ®Google Scholar
• Keats MM, Mukherjee S. Antiaggressive effect of adjunctive clonazepam in schizophrenia associated with seizure disorder. J Clin Psychiatry. 1988 Mar;49(3):117–118.
   PubMed Web of Science ®Google Scholar
• Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996 Oct;35(10):1314–1321.
   PubMed Web of Science ®Google Scholar
• Lara DR, Cruz MR, Xavier F, et al. Allopurinol for the treatment of aggressive behaviour in patients with dementia. Int Clin Psychopharmacol. 2003 Jan;18(1):53–55.
   PubMed Web of Science ®Google Scholar
• Lara DR, Belmonte-de-Abreu P, Souza DO. Allopurinol for refractory aggression and self-inflicted behaviour. J Psychopharmacol. 2000 Mar;14(1):81–83.
   PubMed Web of Science ®Google Scholar
• Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand. 1995 May;91(5):348–351.
   PubMed Web of Science ®Google Scholar
• Jones RM, Arlidge J, Gillham R, et al. Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatry. 2011 Feb;198(2):93–98.
   PubMed Web of Science ®Google Scholar
• Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003 Aug;42(8):886–894.
   PubMed Web of Science ®Google Scholar
• MTA. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073–1086.
   PubMed Web of Science ®Google Scholar
• Bain L, Stroud C. Enabling discovery, development, and translation of treatments for cognitive dysfunction in depression: workshop summary. Washington (DC) 2015. eng.
   Google Scholar
• Blader JC, Schooler NR, Jensen PS, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry. 2009 Dec;166(12):1392–1401.
   PubMed Web of Science ®Google Scholar
• Steiner H, Petersen ML, Saxena K, et al. Divalproex sodium for the treatment of conduct disorder: A randomized controlled clinical trial. J Clin Psychiatry. 2003 Oct;64(10):1183–1191.
   PubMed Web of Science ®Google Scholar
• Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001 Mar;62(3):199–203.
   PubMed Web of Science ®Google Scholar
• Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010 Mar;35(4):990–998.
   PubMed Web of Science ®Google Scholar
• Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003 Jun;28(6):1186–1197.
   PubMed Web of Science ®Google Scholar
• Mattes JA. Oxcarbazepine in patients with impulsive aggression: A double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2005 Dec;25(6):575–579.
   PubMed Web of Science ®Google Scholar
• Stanford MS, Houston RJ, Mathias CW, et al. A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression. Psychiatry Res. 2001 Sep 20;103(2–3):193–203.
   PubMed Web of Science ®Google Scholar
• Barratt ES, Stanford MS, Felthous AR, et al. The effects of phenytoin on impulsive and premeditated aggression: A controlled study. J Clin Psychopharmacol. 1997 Oct;17(5):341–349.
   PubMed Web of Science ®Google Scholar
• New AS, Buchsbaum MS, Hazlett EA, et al. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology (Berl). 2004 Nov;176(3–4):451–458.
   PubMed Web of Science ®Google Scholar
• Barzman DH, Findling RL. Pharmacological treatment of pathologic aggression in children. Int Rev Psychiatry. 2008 Apr;20(2):151–157.
   PubMed Web of Science ®Google Scholar
• Patel BD, Barzman DH. Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression: A review. Psychiatr Q. 2013 Dec;84(4):407–415.
   PubMed Web of Science ®Google Scholar
• Ward F, Tharian P, Roy M, et al. Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: A systematic review. Res Dev Disabil. 2013 Dec;34(12):4293–4303.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004 Jul;65(7):903–907.
   PubMed Web of Science ®Google Scholar
• Armenteros JL, Lewis JE. Citalopram treatment for impulsive aggression in children and adolescents: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2002 May;41(5):522–529.
   PubMed Web of Science ®Google Scholar
• McGuire K, Fung LK, Hagopian L, et al. Irritability and problem behavior in autism spectrum disorder: A practice pathway for pediatric primary care. Pediatrics. 2016 Feb;137(Suppl 2):S136–S148.
   PubMed Web of Science ®Google Scholar
• Adewole T, Brittain ST, Johnson JK, et al. Long-term efficacy and safety of extended-release molindone (SPN-810) to manage impulsive aggression (IA) in children with attention deficit hyperactivity disorder (ADHD). Poster presented at: American Academy of Child and Adolescent Psychiatry; October 24–29; New York, NY: Supernus Pharmaceuticals, Inc.; 2016.
   Google Scholar
• Adewole T, Brittain ST, Johnson JK, et al. Long-term efficacy and safety of extended-release molindone (SPN-810) to manage impulsive aggression (IA) in children with attention deficit hyperactivity disorder (ADHD). Poster presented at: American Society of Clinical Psychopharmacology; May 29-Jun 2; Miami, FL: Supernus Pharmaceuticals, Inc.; 2017.
   Google Scholar
• Blair RJ. The roles of orbital frontal cortex in the modulation of antisocial behavior. Brain Cogn. 2004 Jun;55(1):198–208.
   PubMed Web of Science ®Google Scholar
• Haller J. The neurobiology of abnormal manifestations of aggression–A review of hypothalamic mechanisms in cats, rodents, and humans. Brain Res Bull. 2013 Apr;93:97–109.
   PubMed Web of Science ®Google Scholar
• Bagnall A, Fenton M, Kleijnen J, et al. Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan;24(1):CD002083.
   Google Scholar
• Moban (molindone hydrochloride tablets, USP) prescribing information. Chadds Ford, PA: Endo Pharmaceuticals, Inc; 2009.
   Google Scholar
• Department of Health and Human Services. Food and Drug Administration. Determination that Moban (molindone hydrochloride) tablets (5 milligrams, 10 milligrams, 25 milligrams, 50 milligrams, and 100 milligrams) and capsules (5 milligrams, 10 milligrams, and 25 milligrams) were not withdrawn from sale for reasons of safety or effectiveness. Federal Register. 2013;78(215):66742–66743.
   Google Scholar
• Brittain ST, Stocks JD, Johnson JK, et al. Adjunctive extended-release molindone (SPN-810) to manage impulsive aggression in children with attention deficit hyperactivity disorder (ADHD) receiving optimized stimulant monotherapy and behavioral therapy. Poster presented at: American Academy of Neurology; April 15–21; Vancouver, BC, Canada: Supernus Pharmaceuticals, Inc.; 2016.
   Google Scholar
• Yu C, Gopalakrishnan G. In vitro pharmacological characterization of SPN-810M (molindone). J Exp Pharmacol. 2018 Nov;10:65–73.
   PubMedGoogle Scholar
• Seo D, Patrick CJ, Kennealy PJ. Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Behav. 2008 Oct;13(5):383–395.
   PubMed Web of Science ®Google Scholar
• Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008 Nov;165(11):1420–1431.
   PubMed Web of Science ®Google Scholar
• Lee R, Arfanakis K, Evia AM, et al. White matter integrity reductions in intermittent explosive disorder. Neuropsychopharmacology. 2016 Oct;41(11):2697–2703.
   PubMed Web of Science ®Google Scholar